Wanbury Ltd
WANBURYWanbury Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting.
The sharpest disagreement: profits are rising, but only 42% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (15 weeks in) while the P/E sits at the 56th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +1,500.0% year on year, and 42% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Wanbury Ltd trades at ₹294, in a confirmed uptrend and 15 weeks into that stage. That is +11.1% against its own 200-day average. It sits at 75% of a 52-week range of ₹177 to ₹333. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 11 straight weeks.
Today the stock is in a confirmed uptrend — week 15 of stage 2, confirmed. At ₹294 it trades +11.1% versus its 200-day average and sits at 75% of its 52-week range (₹177–₹333).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +630% while the NIFTY 500 moved +282% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 11 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Wanbury Ltd trades at 23.9× P/E, mid-range by its own standards (56th percentile). Its long-run median P/E is 21.8×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 23.9× is mid-range by its own standards (56th percentile), against a long-run median of 21.8× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −45.5% against a +9.0% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 10y, of the +21.3%/yr price move, ~+23.4%/yr came from earnings growth and ~−2.1 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Wanbury Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −80.0% at the trough to +1500.0% off a 5-quarter-old trough (single-quarter readings), ROCE slipping at 37.0%. The read is built from 8 quarters across 3 curves, on partial evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +7.7% | +5.5% | +10.3% | +9.1% |
| Profit | −44.6% | −27.4% | −13.5% | +26.3% |
| EPS | −45.5% | −28.0% | −18.4% | +19.3% |
| Share price | +9.0% | +77.4% | +28.1% | +21.3% |
4-Factor Sector Score
71.2/100 — rank 2 of 14 in Pharma - API · 73% evidence confidence
Wanbury Ltd scores 71.2 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 2. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 25.7 + 19.5 + 12.1 + 13.9 = 71.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Wanbury Ltd reported ₹162 Cr of revenue in the Dec 25 quarter, +21.8% year on year. Over 10 years it has compounded at 9.1% a year. The last full year, FY25, came in at ₹600 Cr. The last four reported quarters add to ₹657 Cr.
FY25 revenue came in at ₹600 Cr (+7.7% on the year), capping 10 years at 9.1% compound. The latest quarter (Dec 25) printed ₹162 Cr, +21.8% year on year.
Pace check: the last four quarters averaged +17.3% growth against the decade's 9.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +16.5% over the last 4 quarters against +7.5%/yr over the last 8 — accelerating; TTM profit +45.5% vs +66.8%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Wanbury Ltd's operating margin is 16.0% in the Dec 25 quarter, +6.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 12 fiscal years the operating margin has ranged −18.0% to 13.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 16.0%, +6.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged −18.0%–13.0%, and FY25's 13.0% is the top of that band — a record year.
Why the margin moved: operating margin went +6.6 pp year on year while gross margin went +4.4 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Wanbury Ltd earned ₹16.0 Cr of net profit in the Dec 25 quarter, +1,500.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY25 profit was ₹31.0 Cr. The 10-year compound rate is 26.3%. That is 9.9% of the quarter's revenue. The same quarter a year earlier earned ₹1.0 Cr.
Dec 25 profit was ₹16.0 Cr, +1,500.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY25 printed ₹31.0 Cr (−44.6%), and the 10-year compound rate is 26.3%.
Why profit moved: revenue contributed +21.8% and the margin +6.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +686.6% vs revenue +17.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 42% of Wanbury Ltd's reported profit arrived as operating cash — a gap worth watching. In FY25 that was ₹26.0 Cr of operating cash against ₹31.0 Cr of profit. After ₹49.0 Cr of capital spending, ₹−23.0 Cr was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of ₹26.0 Cr against reported profit of ₹31.0 Cr, leaving free cash of ₹−23.0 Cr after ₹49.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 42% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 42%: the cash cycle stretched 122 days between FY20 and FY25 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 122 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Wanbury Ltd's cash conversion cycle runs −55 days in FY25, up from −177 days in FY20. Capital spending ran ₹75.0 Cr over the last 3 years. At FY25 sales of ₹600 Cr each day of that cycle holds about ₹1.6 Cr, so roughly ₹−90.0 Cr sits inside the business at any moment.
FY25: debtors at 70 days, inventory at 47 days — roughly 1.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −55 days, looser than FY20's −177.
The full loop: cash goes out to suppliers and production on day 0; stock waits 47 days to sell; customers pay about 70 days after that; and suppliers themselves are paid at 172 days — netting out to the −55-day cycle.
In money terms: at FY25 sales of ₹600 Cr, each day of the cycle holds about ₹1.6 Cr — so the −55-day loop keeps roughly ₹−90.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹75.0 Cr over the last 3 fiscal years against ₹38.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹5.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Wanbury Ltd earns a ROCE of 37% in FY25. That is up from a trough of −1% in FY18. Return on invested capital clears the cost of that capital by +16.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 5.2% net margin on 1.45× asset turns.
FY25 ROCE is 37%, recovered from a FY18 trough of −1% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 5.2% net margin × 1.45× asset turns × 7.02× balance-sheet leverage ≈ 52.9% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 28.3% − 12.0% = a +16.3 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Wanbury Ltd carries total debt of ₹224 Cr against shareholder equity of ₹144 Cr as of Mar 26, a debt-to-equity of 1.56. On the annual view that ratio went from 27.00 in FY22 to 1.56 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹224 Cr against shareholder equity of ₹144 Cr — a debt-to-equity of 1.56. On the annual view, debt-to-equity went from 27.00 (FY22) to 1.56 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 3.2 points of Wanbury Ltd over 8 quarters, the biggest move on the register. That takes promoters to 43.0% of the company. Foreign institutions moved +0.7 points over the same window, to 0.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +3.2 points over 8 quarters to 43.0%; Foreign institutions: +0.7 points over 8 quarters to 0.9%; Domestic institutions: +0.1 points over 8 quarters to 0.1%.
Why the register moved: promoters drove it (+3.2 points), alongside foreign institutions (+0.7 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Wanbury Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Senores Pharmaceuticals LtdSENORES | 73.8/100Favorable setup75% evidence | LEADER | 32.4/35 Revenue 50.9% · PAT 92.7% · OPM change 5 pp 95% evidence | 16.4/25 ROCE 15.1% · OPM 30% 76% evidence | 9.4/20 P/E 47.6× · PEG — 15% evidence | 15.6/20 RS sector 19.5% · RS bench 44.3% · 1Y 95.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.4 + 16.4 + 9.4 + 15.6 = 73.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Wanbury Ltdthis pageWANBURY | 71.2/100Favorable setup73% evidence | TURNING | 25.7/35 Revenue 16.5% · PAT 45.5% · OPM change 6 pp 71% evidence | 19.5/25 ROCE 36.6% · OPM 16% 95% evidence | 12.1/20 P/E 23.9× · PEG — 50% evidence | 13.9/20 RS sector 5.3% · RS bench 12.9% · 1Y 20.1%7 of 11 weeks ahead 70% evidence |
| Exact sum: 25.7 + 19.5 + 12.1 + 13.9 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3Innova Captab LtdINNOVACAP | 65.1/100Favorable setup96% evidence | LEADER | 22.2/35 Revenue 31.1% · PAT 10.2% · OPM change 0 pp 88% evidence | 15.6/25 ROCE 15% · OPM 15% 100% evidence | 13.8/20 P/E 39.7× · PEG 1.01 100% evidence | 13.5/20 RS sector -1.4% · RS bench 19.9% · 1Y 7.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 15.6 + 13.8 + 13.5 = 65.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Jagsonpal Pharmaceuticals LtdJAGSNPHARM | 56.9/100Mixed-positive evidence81% evidence | TURNING | 15.7/35 Revenue 3.2% · PAT -24.6% · OPM change 2 pp 95% evidence | 18.2/25 ROCE 22.7% · OPM 21% 95% evidence | 11.2/20 P/E 32.4× · PEG — 50% evidence | 11.8/20 RS sector 0.7% · RS bench 9.7% · 1Y -12.3%10 of 10 weeks ahead 70% evidence |
| Exact sum: 15.7 + 18.2 + 11.2 + 11.8 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Fermenta Biotech LtdFERMENTA | 56.3/100Mixed-positive evidence70% evidence | TURNING | 11.4/35 Revenue 11.9% · PAT -6.6% · OPM change -10 pp 83% evidence | 18.0/25 ROCE 20.6% · OPM 16% 95% evidence | 11.0/20 P/E 23.4× · PEG — 15% evidence | 15.9/20 RS sector 15.7% · RS bench 49.3% · 1Y 33.5%3 of 7 weeks ahead 70% evidence |
| Exact sum: 11.4 + 18 + 11 + 15.9 = 56.3 · Decision use: Price leads the evidence: RS versus the benchmark is 49.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Ind-Swift Laboratories LtdINDSWFTLAB | 55.3/100Mixed-positive evidence83% evidence | BREAKING OUT | 22.3/35 Revenue 100% · PAT -80% · OPM change 19 pp 83% evidence | 6.5/25 ROCE 4.7% · OPM 12% 95% evidence | 6.5/20 P/E 39.4× · PEG — 50% evidence | 20.0/20 RS sector 39.4% · RS bench 68% · 1Y 114.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 6.5 + 6.5 + 20 = 55.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Aarti Drugs LtdAARTIDRUGS | 49.3/100Mixed-negative evidence94% evidence | TURNING | 18.2/35 Revenue 10.5% · PAT 1.1% · OPM change 1 pp 100% evidence | 10.6/25 ROCE 11.9% · OPM 14% 100% evidence | 13.3/20 P/E 20× · PEG 2.4 100% evidence | 7.2/20 RS sector -10.7% · RS bench 0.7% · 1Y -21.4%4 of 10 weeks ahead 70% evidence |
| Exact sum: 18.2 + 10.6 + 13.3 + 7.2 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Anuh Pharma LtdANUHPHR | 47.8/100Mixed-negative evidence77% evidence | ASLEEP | 16.6/35 Revenue 16.5% · PAT -12.8% · OPM change 1 pp 83% evidence | 11.1/25 ROCE 14.9% · OPM 10% 95% evidence | 13.1/20 P/E 21.9× · PEG — 50% evidence | 7.0/20 RS sector -5.4% · RS bench -2.9% · 1Y -20%0 of 10 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.1 + 13.1 + 7 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Beta Drugs LtdBETA | 45.6/100Mixed-negative evidence76% evidence | TURNING | 11.7/35 Revenue -11.3% · PAT -14.8% · OPM change 2 pp 95% evidence | 18.6/25 ROCE 19.2% · OPM 22% 76% evidence | 7.1/20 P/E 51× · PEG — 50% evidence | 8.2/20 RS sector -17.9% · RS bench 35.1% · 1Y 30.5%9 of 10 weeks ahead 70% evidence |
| Exact sum: 11.7 + 18.6 + 7.1 + 8.2 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Kopran LtdKOPRAN | 42.1/100Mixed-negative evidence77% evidence | TURNING | 16.6/35 Revenue 8.3% · PAT -34.2% · OPM change 4 pp 83% evidence | 9.6/25 ROCE 6.7% · OPM 14% 95% evidence | 8.1/20 P/E 35.8× · PEG — 50% evidence | 7.8/20 RS sector -17.6% · RS bench 19.4% · 1Y 10.6%11 of 11 weeks ahead 70% evidence |
| Exact sum: 16.6 + 9.6 + 8.1 + 7.8 = 42.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Gujarat Themis Biosyn LtdGUJTHEM | 39.8/100Mixed-negative evidence89% evidence | ASLEEP | 14.8/35 Revenue 8.6% · PAT -6.1% · OPM change 2 pp 88% evidence | 18.3/25 ROCE 17.9% · OPM 44% 100% evidence | 6.4/20 P/E 83.6× · PEG 2.77 65% evidence | 0.3/20 RS sector -22.1% · RS bench -4.7% · 1Y -1.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 18.3 + 6.4 + 0.3 = 39.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Themis Medicare LtdTHEMISMED | 28.7/100Adverse evidence68% evidence | BREAKING OUT | 13.0/35 Revenue -15.6% · PAT -80% · OPM change 15.7 pp 62% evidence | 2.4/25 ROCE 2.7% · OPM 4.9% 95% evidence | 8.5/20 P/E 587× · PEG — 15% evidence | 4.8/20 RS sector -17.2% · RS bench 0.9% · 1Y -10%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 2.4 + 8.5 + 4.8 = 28.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aarti Pharmalabs LtdAARTIPHARM | 27.4/100Adverse evidence90% evidence | ASLEEP | 7.3/35 Revenue -14% · PAT -31.3% · OPM change -7 pp 88% evidence | 11.3/25 ROCE 10.7% · OPM 19% 100% evidence | 3.3/20 P/E 34.2× · PEG 5.52 100% evidence | 5.5/20 RS sector -10.7% · RS bench -11.7% · 1Y -29.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 7.3 + 11.3 + 3.3 + 5.5 = 27.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Orchid Pharma LtdORCHPHARMA | 19.0/100Adverse evidence90% evidence | TURNING | 5.9/35 Revenue -11.8% · PAT -79.8% · OPM change -1 pp 88% evidence | 2.9/25 ROCE 2.6% · OPM 11% 100% evidence | 2.7/20 P/E 184× · PEG 4.09 100% evidence | 7.5/20 RS sector -19.8% · RS bench 29.8% · 1Y 38.9%11 of 11 weeks ahead 70% evidence |
| Exact sum: 5.9 + 2.9 + 2.7 + 7.5 = 19 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Wanbury Ltd's share price today?
Wanbury Ltd trades at ₹294, +9.0% over the past year. The company is valued at ₹1,026 Cr. The stock sits at 75% of its 52-week range of ₹177–₹333, +11.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 15 weeks in. — as of 31 July 2026.
What were Wanbury Ltd's latest quarterly results?
Wanbury Ltd reported revenue of ₹162 Cr and net profit of ₹16.0 Cr for the Dec 25 quarter. Revenue rose 21.8% and profit rose 1,500.0% year on year. Earnings per share were ₹4.52. The operating margin was 16.0%, 6.0 pp higher than a year earlier. — as of 31 July 2026.
What is Wanbury Ltd's revenue?
Wanbury Ltd reported revenue of ₹162 Cr in the Dec 25 quarter, +21.8% year on year. For the full FY25 fiscal year, revenue was ₹600 Cr (+7.7%). Over the last 10 years revenue compounded at 9.1% a year. — as of 31 July 2026.
What is Wanbury Ltd's profit?
Wanbury Ltd earned ₹16.0 Cr of net profit in the Dec 25 quarter, +1,500.0% year on year — the 3rd straight quarter of growth. Full-year FY25 profit was ₹31.0 Cr. The operating margin ran 16.0% in the latest quarter. — as of 31 July 2026.
What is Wanbury Ltd's market cap?
Wanbury Ltd's market capitalisation is ₹1,026 Cr at a share price of ₹294. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Wanbury Ltd's P/E ratio?
Wanbury Ltd trades at a P/E of 23.9×, at the 56th percentile of its own 10-year range, against a long-run median of 21.8×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Wanbury Ltd pay a dividend?
No — Wanbury Ltd has recorded a dividend payout of 0% of profit in each of its last 12 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Wanbury Ltd overvalued?
On its own history, Wanbury Ltd looks mid-range against its own history: its P/E of 23.9× sits at the 56th percentile of its 10-year range (long-run median 21.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Wanbury Ltd growing?
Yes — Wanbury Ltd is growing: latest-quarter revenue +21.8% year on year, profit +1,500.0%, and the margin +6.0 pp at 16.0%. The 10-year compound rates are 9.1% (revenue) and 26.3% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Wanbury Ltd performing?
Wanbury Ltd is in a confirmed uptrend, 15 weeks in. Its latest quarter's revenue rose 21.8% and profit rose 1,500.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 11 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Wanbury Ltd in?
Turning around — profit growth swung from −80.0% at the trough to +1500.0% off a 5-quarter-old trough (single-quarter readings), ROCE slipping at 37.0%. The read comes from the last 12 quarters of growth (revenue growth +16.5% latest, profit growth +1,500.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Wanbury Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 15 of stage 2), trading +11.1% versus its 200-day average and at 75% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Wanbury Ltd beating the market?
On recent form, yes — Wanbury Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 11 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +630% against the NIFTY 500's +282% — ahead of the index over the full window. — as of 31 July 2026.
Will Wanbury Ltd's share price go up?
This page publishes no price forecast for Wanbury Ltd. What it measures instead: the share price is ₹294, the price is in a confirmed uptrend 15 weeks in. Its P/E of 23.9× sits at the 56th percentile of its own 10-year range. — as of 31 July 2026.
Who owns Wanbury Ltd?
Promoters hold 43.0% of Wanbury Ltd, foreign institutions 0.9%, domestic institutions 0.1% and the public 56.0% (latest quarter). The biggest move on the register over the last two years: Promoters added 3.2 points over 8 quarters. — as of 31 July 2026.
Does Wanbury Ltd have too much debt?
It carries real leverage — Wanbury Ltd's debt-to-equity is 3.03, and operating profit covers the interest bill 2×. FY25 borrowings were ₹179 Cr against equity of ₹59.0 Cr. Read the returns on this page with that leverage in mind — as of 31 July 2026.
What is Wanbury Ltd's capex?
Wanbury Ltd spent ₹75.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹49.0 Cr, with ₹5.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Wanbury Ltd's cash flow?
Wanbury Ltd generated ₹26.0 Cr of operating cash flow in FY25 and ₹−23.0 Cr of free cash flow after ₹49.0 Cr of capital spending. Reported profit that year was ₹31.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Wanbury Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 42% of Wanbury Ltd's reported profit arrived as operating cash. In FY25, operating cash was ₹26.0 Cr against reported profit of ₹31.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
Where is Wanbury Ltd in its business cycle?
Wanbury Ltd's FY25 operating margin was 13.0%, against a 12-year band of −18.0%–13.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 16.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Wanbury Ltd story?
The sharpest disagreement: profits are rising, but only 42% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Wanbury Ltd a stock worth studying right now?
This is not investment advice. The machine read: Wanbury Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.